PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7073302

Oxalosis in infancy.

M C Morris·T L Chambers·P W Evans·P N Malleson·J R Pincott·G A Rose
View original source ↗Export metadata ↓

Abstract

We describe 3 infants with nephrocalcinosis and terminal renal failure. In all 3 there was widespread oxalate deposition: biochemical evidence of primary hyperoxaluria was sought but the presence of severe renal failure and the lack of established normal values for urinary and plasma oxalate and glycollate in infants made this diagnosis difficult to establish.

Explore related subjects

Calcium Metabolism DisordersCalcium OxalateFemaleHumansInfantKidney Failure, ChronicMaleNephrocalcinosisCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M C Morris, T L Chambers, P W Evans, P N Malleson, J R Pincott, G A Rose. 1982. Oxalosis in infancy.. https://doi.org/10.1136/adc.57.3.224

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Superimposition of nutcracker syndrome in a hematuric child with idiopathic hypercalciuria and urolithiasis.

We report a 5-year-old girl with idiopathic hypercalciuria who developed gross hematuria and left flank pain despite normalization of calciuria, a renal stone, and microscopic hematuria. She was found to have nutcracker syndrome by renal Doppler ultrasound, which revealed the significant differences of the peak blood flow velocities in the two portions of the left renal vein.

Calcium Metabolism Disorders↗
PubMed2006

The calcium-sensing receptor and related diseases.

The calcium-sensing receptor (CASR) adjusts the extracellular calcium set point regulating PTH secretion and renal calcium excretion. The receptor is expressed in several tissues and is also involved in other cellular functions such as proliferation, differentiation and other hormonal secretion. High extracellular calcium levels activate the receptor resulting in modulation of several signaling pathways depending on the target tissues. Mutations in the CASR gene can result in gain or loss of receptor function. Gain of function mutations are associated to Autossomal dominant hypocalcemia and Bartter syndrome type V, while loss of function mutations are associated to Familial hypocalciuric hypercalcemia and Neonatal severe hyperparathyroidism. More than one hundred mutations were described in this gene. In addition to calcium, the receptor also interacts with several ions and polyamines. The CASR is a potential therapeutic target to treatment of diseases including hyperparathyroidism and osteoporosis, since its interaction with pharmacological compounds results in modulation of PTH secretion.

Calcium Metabolism Disorders↗